P14ARF Induces P53-independent Growth Arrest By Modulating The Activities Of The E4F And E2F Transcription Factors
Funder
National Health and Medical Research Council
Funding Amount
$235,500.00
Summary
Cutaneous malignant melanoma is an important public health problem, affecting 1 in 30 Australians at some time in their lives, and the incidence of this disaese is increasing rapidly. Approximately 10% of people in Australia are at high risk of developing melanoma because they carry a faulty gene. Many of these melanoma-prone individuals carry a single mutation that can disrupt two genes, p16INK4a and p14ARF, that are involved in regulating the growth of cells via different pathways. The role of ....Cutaneous malignant melanoma is an important public health problem, affecting 1 in 30 Australians at some time in their lives, and the incidence of this disaese is increasing rapidly. Approximately 10% of people in Australia are at high risk of developing melanoma because they carry a faulty gene. Many of these melanoma-prone individuals carry a single mutation that can disrupt two genes, p16INK4a and p14ARF, that are involved in regulating the growth of cells via different pathways. The role of p16INK4a in maintaining cell cycle control is well understood and the many functions of this gene are under intense investigation. In contrast, the functions of p14ARF in normal cell regulation are not well understood. We will be analysing in detail how p14ARF protects the cell from uncontrolled growth and inhibits cancer development. Our research will dissect the functions of p14ARF and determine the protein partners that co-operate with p14ARF in maintaining normal cell growth. This work is essential to our understanding of normal cell proliferation and melanoma development and will provide clinically useful information regarding the biology of human cancer.Read moreRead less
Transcriptional And Cell Cycle Control Of Erythropoiesis By E2F4
Funder
National Health and Medical Research Council
Funding Amount
$447,750.00
Summary
The balance in the number of cells in our body is a carefully regulated process which, when disturbed, can lead to a number of life-threatening diseases such as cancer. Through genetic studies in the mouse, we previously identified E2F4 as a protein that is required for the correct number of red blood cells in the body. Lack of E2F4 results in anaemia in the mouse embryo. We have studied these mice as a model to understand how cell production in the body can be controlled. In recent studies, we ....The balance in the number of cells in our body is a carefully regulated process which, when disturbed, can lead to a number of life-threatening diseases such as cancer. Through genetic studies in the mouse, we previously identified E2F4 as a protein that is required for the correct number of red blood cells in the body. Lack of E2F4 results in anaemia in the mouse embryo. We have studied these mice as a model to understand how cell production in the body can be controlled. In recent studies, we have identified proliferation defects and in particular cell division cycle defects as the major cause for the decreased production of red blood cells in the embryo. In addition, we have utilised gene microarray technology to survey which genes change in the absence of E2F4 by comparing gene expression profiles in normal and E2F4 deficient mice. These studies have identified a large number of genes that could be molecular targets for E2F4 and whose defective expression could be ultimately responsible for the anaemia of these mice. Importantly, our data suggests a completely novel function for E2F4 in controlling the switching on of genes required for cell division. In this proposal, we describe approaches to characterise how E2F4 controls the cell division cycle to identify the exact process(es) it may control such as DNA replication or separation of chromosomes into daughter cells. We will also test our hypothesis for a novel role for E2F4 in being able to switch on genes in nucleated red blood cell. Finally, we describe gene microarray experiments and a new promoter microarray approach to close in on the molecules directly required for the E2F4 control of red blood cell production. Because defects in the E2F family of proteins or the proteins that regulate them, the retinoblastoma, pRB family, have been implicated as central for cancer development, these studies will have broad implications for therapeutic targeting of this pathway in cancer.Read moreRead less
The Role Of The PRB/E2F Pathway In Erythropoiesis And Cell Cycle Control
Funder
National Health and Medical Research Council
Funding Amount
$272,036.00
Summary
Circulating blood contains two major types of cells. Red blood cells supply the oxygen required by all cells in our body to survive and white blood cells protect our body from invasion by foreign organisms. The balance in the number of these cells in our blood is a carefully regulated process which, when disturbed, can lead to a number of life-threatening blood diseases. Uncontrolled overgrowth of blood cells results in a particular type of cancer known as leukaemia. In contrast, when there is a ....Circulating blood contains two major types of cells. Red blood cells supply the oxygen required by all cells in our body to survive and white blood cells protect our body from invasion by foreign organisms. The balance in the number of these cells in our blood is a carefully regulated process which, when disturbed, can lead to a number of life-threatening blood diseases. Uncontrolled overgrowth of blood cells results in a particular type of cancer known as leukaemia. In contrast, when there is an insufficient number of red blood cells, not enough oxygen reaches cells from the brain and other vital organs and results in a condition known as anaemia. We have genetically engineered a mouse that lack the protein known as E2F4 and is unable to produce enough red blood cells and suffers from anaemia. This protein, E2F4, controls genes essential for the decision of cells to start or stop growing and multiplying. The E2F4-deficient mice therefore provide a new and powerful model to understand the mechanism by which disturbance of red blood cell numbers can lead to diseases such as leukaemia and other diseases of the blood. Identification of the genes controlled by E2F4 may provide new targets for the development of therapeutic drugs to combat these diseases.Read moreRead less
Development Of A Novel Therapy For The Treatment Of Epidermal Squamous Cell Carcinoma
Funder
National Health and Medical Research Council
Funding Amount
$432,750.00
Summary
Squamous cell carcinomas (SCC) are the most common life-threatening form of skin cancer in Australia. SCCs commonly arise in areas of the body that have been exposed to excessive amounts of UV irradiation. The cells of the skin from which SCCs are derived are called keratinocytes. UV irradiation causes lesions within these cells such that their growth and maturation are disrupted leading to deregulated growth and maturation and hence tumour formation. We have previously identified a protein, E2F ....Squamous cell carcinomas (SCC) are the most common life-threatening form of skin cancer in Australia. SCCs commonly arise in areas of the body that have been exposed to excessive amounts of UV irradiation. The cells of the skin from which SCCs are derived are called keratinocytes. UV irradiation causes lesions within these cells such that their growth and maturation are disrupted leading to deregulated growth and maturation and hence tumour formation. We have previously identified a protein, E2F, that is central to this process and whose inhibition leads to decreased cancer cell growth. During the course of these studies we noted that the deregulation of E2F could also lead to the disruption of keratinocyte maturation. This led us to propose that the inhibition of E2F in SCCs may result in both decreased cancer cell growth as well as the reinstatement of a normal maturation process. this would make E2F inhibitors a very attractive therapeutic for treating SCC. In the present study we aim to explore the ability and the mechanism by which E2F modulates keratinocyte proliferation and maturation. This will be done in vitro as well as in animal models of SCC. These studies will be required in order to take the E2F inhibitors into clinical trials.Read moreRead less